Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.42 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 4/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 3/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24529531 | 1.00 | HCRTR2 (0.52) | HCRTR2DYRK1ATGFBR1TGFBR2RET | |
| SCHEMBL27181434 | 0.79 | SYK (0.39) | HCRTR2OPRK1 | |
| SCHEMBL24529318 | 0.79 | SYK (0.39) | HCRTR2OPRK1 | |
| SCHEMBL24529200 | 0.79 | TRIM33 (0.41) | DYRK1ATGFBR1MERTKAXLFLT3 | |
| SCHEMBL24529205 | 0.76 | HCRTR2 (0.35) | HCRTR2OPRK1JAK2 | |
| SCHEMBL29723821 | 0.76 | HCRTR2 (0.35) | HCRTR2OPRK1JAK2 | |
| SCHEMBL27180720 | 0.76 | HCRTR2 (0.35) | HCRTR2OPRK1JAK2 | |
| SCHEMBL24529535 | 0.76 | DYRK1A (0.47) | HCRTR2DYRK1ATGFBR1TGFBR2RET | |
| SCHEMBL29102774 | 0.74 | HCRTR2 (0.41) | HCRTR2NR4A2PIK3CA | |
| SCHEMBL24387093 | 0.74 | HCRTR2 (0.41) | HCRTR2NR4A2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | disclosed |
| EP-4262788-A1 | UREA OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022132696-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, UTS2R | HCRTR2 2/4885DYRK1A 3348/4885TGFBR1 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.